Allard van Renterghem

Congrats Seba! 🙌🙌🙌

Thanks to all friends, collaborators and mentors involved in this project! @nkinl.bsky.social

In liver metastases, this circuit is shut down. IL-18–driven activation of liver Vδ1⁺ γδ T cells is actively suppressed by cancer cell-derived IL18BP, helping explain why liver metastases predict poor responses to immune checkpoint blockade.

Strikingly, we found that IL18 was able to activate liver-resident γδ T cells, whereas Vδ1⁺ γδ T cells from the intestines do not show this response. This shows are these cells not the same across organs and metastatic sites!

We identify in patients, IL-18 expression was associated with response to immune checkpoint blockade selectively in patients with liver metastases, highlighting it's importance in shaping liver-specific immunity (and potential as a target 💥1️⃣8️⃣💥)

We identify Vδ1⁺ γδ T cells as key tissue sentinels in the liver, capable of shifting the balance from tolerance to immunological control 🚨👮‍♀️. Vδ1⁺ γδ T cells are known to express PD-1, can act as effectors of ICB response in MMR-d cancers. The signals driving their activation are poorly understood.

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer van Renterghem et al. investigate the impact of liver metastases on immunity in MMR-d/MSI-hi patients treated with ICB. They show that IL18 activates liver-derived Vδ1+ T cells and predicts ICB benefi...

Why do patients with liver metastases respond so poorly to cancer immunotherapy?
Here we find a new immunological mechanism in MMR-d cancers centering on IL-18 and γδ T cells.👇 www.cell.com/cell-reports... @cp-cellrepmed.bsky.social

Thanks to all friends, collaborators and mentors involved in this project! @nkinl.bsky.social

In liver metastases, this circuit is shut down. IL-18–driven activation of liver Vδ1⁺ γδ T cells is actively suppressed by cancer cell-derived IL18BP, helping explain why liver metastases predict poor responses to immune checkpoint blockade.

Strikingly, we found that IL18 was able to activate liver-resident Vδ1⁺ γδ T cells, whereas Vδ1⁺ γδ T cells from the intestines do not show this response. This shows γδ T cells that are not the same across organs.

We identify in patients, IL-18 expression was associated with response to immune checkpoint blockade selectively in patients with liver metastases, highlighting it's importance in driving liver immunity

We pinpoint Vδ1⁺ γδ T cells as key sentinels in the liver, capable of shifting the balance from tolerance to immunological control. γδ T cells are known to express PD-1, and can act as effectors of ICB response in MMR-d cancers. However te signals driving their activation are poorly understood.

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer @cp-cellrepmed.bsky.social
www.cell.com/cell-reports...

Cool martina 👏 excited to read

Taking over the hospital for prideweek with gendercupcakes
@nkinl.bsky.social @florencevb.bsky.social #diversity

Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread Tumor-induced systemic accumulation and polarization of neutrophils to an immunosuppressive phenotype is a potent driver of metastasis formation. Yet,…

💥 Really excited to say that our paper with Karin de Visser and @dewitlab.bsky.social is now online! A beautiful story to culminate years of great collaboration and teamwork at the @nkinl.bsky.social. A 🧵

www.sciencedirect.com/science/arti...

Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer - Nature Spatially resolved transcriptomic profiling of primary tumours and metastases from patients with pancreatic cancer provides insight into the evolutionary progression to metastasis, and the variation in clonal architecture within and between individuals.

Nature research paper: Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer

https://go.nature.com/4jonL1b

What kind of policies and measures to promote diversity and equality are in place at your institutes? Would love to connect and happy to share some of the initiatives that help make the @nkinl.bsky.social an even better place :)

While awareness amongst healthcare professionals and researchers is a great start, there’s definitely a need to tackle discrimination on a policy and institutional level.

While diversity initiatives are under attack, at the netherlands cancer institute (@nkinl.bsky.social) we firmly believe in creating an inclusive & diverse environment! Together with Humanity in Action we hosted a workshop about recognizing and prevent discrimination in healthcare & academia

Implantation of engineered adipocytes suppresses tumor progression in cancer models - Nature Biotechnology Adipose manipulation transplantation can reduce tumor growth and proliferation in vitro and in mouse models.

Implantation of engineered adipocytes suppresses tumor progression in cancer models - @nadavahituv.bsky.social go.nature.com/4gqhxvw

The next frontier of T cell therapeutics when the T also stands for tissue-targeting, such as brain or local immune response, via synthetic gene circuits
@science.org

science.org/doi/10.1126/...
science.org/doi/10.1126/...
science.org/doi/10.1126/...